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LETTERS TO THE EDITOR 
Long-Term Digoxin Therapy 
Krum et al, (1) conclude from their obscrvations that "long-term 
therapy with digoxin results in a significant increase in parasympathetic 
activity and a decrease in sympathetic activity in patients with chronic 
heart failure." Without a placebo control group, this conclusion is not 
necessarily valid, although the results are provocative and may justify. 
a properly designed trial, particularly regarding parasympathetic activ- 
ity. Placebo-controlled infusions of digoxin did decrease heart rate, but 
did not alter systemic norepinephrine kinetics or improve baroreflex 
responses in a similar group of patients tudied at our laborato~' (2). 
All other studies using sympathetic markers (both short and long term) 
have been uncontrolled. Without detailed information about clinical 
responses, an appeal to other trials using similar markers is not 
convincing. Changes in cardiac output and blood pressure may influ- 
ence both sympathetic and parasympathctic responses. Hence, even if 
autonomic hanges can bc specifically attributed to digoxin therapy, it
is still quite a leap to imply that the drug has direct neurohormonal 
effects. Finally, it seems from these data that low frequency power 
cannot be used to assess ympathetic activity in such patients. As the 
authors note, this measure reflects both sympathetic and parasympa- 
thetic influences. The demonstrated issociatkm between plasma 
norepinephrine and low frequency powcr should bc ve~ useful to 
investigators planning other studies with heart rate variability. 
STEVEN R. GOLDSMITH, MD, FAC(' 
Director, Cardiolo,~ Division 
Hennepin Counlv Medical ('cnwr 
701 Park Avenue South 
Minneapo{is, Minnesota 55415 
References 
1. Krum tl, Bigger TJ JL. Goldsmith RI.. Packcl M. Effect ot long-term digoxin thelapy oil 
autonomic function in heart lailurc. J Am Coil ('ardiol 1095;25:289-94. 
2. Goldsmith SR. Simon AB. Miller E. Eltec~ of digitalis on norepinephrine kinetics in 
congestive heart failure. J Am Cnll Cardiol 1992:21):858-63. 
Reply 
S. Goldsmith raises questions about our conclusion that long-term 
therapy with digoxin improves autonomic balance in patients with 
chronic heart failure. His concerns appear to be based on the fact that 
our study did not have a control group of patients who were treated 
with placebo. In their study, Goldsmith et al. (1) observed little changc 
in norepinephrine kinetics when patients treated with digoxin werc 
compared with patients treated with placebo. However, Goldsmith ct 
al. examined the effects of only a single dose of digoxin, whereas wc 
evaluated the effects of long-term treatment with the drug. This 
distinction is important because the short-term effects of pharmaco- 
logic interventions in heart failure may bear little relation to the 
long-term effects of these drugs. In fact, our conclusion that long-term 
therapy with digoxin improves autonomic balance in patients with 
chronic heart failure has recently been confirmed by the results of the 
Dutch lbopaminc Multicenter Trial (2), which observed a significant 
decrease in plasma norepinephrine l vels with digoxin in a placebo- 
controlled study. 
Yet, even if we were to confine our attention to the short-term 
effects of digoxin, we believe that the preponderance of evidence 
supports the conclusion that digoxin produces immediate ffects on 
sympathetic and parasympathetic activity. A favorable ffect of digoxin 
on various measures of autonomic balance has been demonstrated by
a number of investigators (3-5) using a variety of different and 
complementa~ techniques. The failure of Goldsmith et al. to detect 
significant changes in sympathetic activity, may be due to the insensi- 
tiviw of the technique of norepinephrine kinetics, whose validity is 
predicated on assumptions of steady state conditions (6) that may not 
be true in patients with heart failure. Furthermore, Goldsmith et al. 
evaluated only seven patients, whereas most studies (including our 
own) evaluated a larger number of patients. Goldsmith et al. (1) did 
observe a decrease in plasma norepinephrine l vels (comparing the 
change in plasma norepinephrine in patients treated with digoxin with 
the change in plasma norepinephrine in patients treated with placebo), 
hut this difference did not reach statistical significance, probably 
because of the small number of subjects tudied. Hence, we believe 
that there is now compelling evidence from many different sources that 
short- and long-term therapy with digoxin has a favorable ffect on 
both sympathetic and parasympathetic activity in patients with chronic 
heart failure. 
Although we do not share Goldsmith's concerns about he primary 
findings of our report, we agree strongly with his conclusion that our 
observations demonstrate an important dissociation in changes in 
plasma norepinephrine and changes in low frequency power (as 
quantified by studies of heart rate variability) during the course of 
digoxin therapy. Hence, low frequency power cannot and should not be 
used as a marker to reflect the activity of the sympathetic nervous 
system. 
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